Micro-encapsulated poly(vinyl alcohol) nanoparticles for rifampicin delivery to the lungs

Tuberculosis is a contagious disease caused by Mycobacterium Tuberculosis and is recognised as a global public health emergency. New approaches are required to improve the chemotherapy of TB, in particular to target the reservoir of M. Tuberculosis that accumulates in alveolar macrophages and lung l...

Full description

Bibliographic Details
Main Author: Sadouki, Fethi
Other Authors: Dailey, Lea Ann ; Jones, Stuart Allen ; Forbes, Benjamin John
Published: King's College London (University of London) 2014
Subjects:
Online Access:http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.676976
id ndltd-bl.uk-oai-ethos.bl.uk-676976
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-6769762017-07-25T03:29:49ZMicro-encapsulated poly(vinyl alcohol) nanoparticles for rifampicin delivery to the lungsSadouki, FethiDailey, Lea Ann ; Jones, Stuart Allen ; Forbes, Benjamin John2014Tuberculosis is a contagious disease caused by Mycobacterium Tuberculosis and is recognised as a global public health emergency. New approaches are required to improve the chemotherapy of TB, in particular to target the reservoir of M. Tuberculosis that accumulates in alveolar macrophages and lung lesions. The aim of this thesis was to develop polymeric nanoparticle-loaded formulations for the delivery of rifampicin to the lungs. Poly (vinyl alcohol) nanospheres (NS) and nanocapsules (NC) were developed using a modified nanoprecipitation method. Both types of nanocarrier were spherical with a mean diameter of ca. 220 nm (NS) and 150 nm (NC). Rifampicin was successfully encapsulated with efficiencies of 29.3 ± 0.7% and 32.3 ± 0.3%, for NS and NCs, respectively. Methods for enhancing the stability and modifying the release of rifampicin were developed. The uptake of the PVA nanocarriers was studied in-vitro using the J774A.1 macrophage-like cell line. After 6 h incubation, the amount of rifampicin imported into macrophages by drug-loaded nanoparticles, containing 1000 μg/ml of drug, was twice (NC) or three times (NS) greater than that attained with rifampicin solution. The drug-loaded PVA nanoparticles were formulated into a powder for pulmonary administration by spray drying into lactose to yield spherical microspheres of ca. 2 μm diameter. The deposition studies of the spray dried powders, carried out using a modified twin stage impinger, showed that the NS-loaded-microspheres had a better deposition profile than the NC-loaded microspheres. This work generated novel PVA nanocarriers, demonstrated that they are effective in targeting rifampicin to macrophages and exemplified their formulation as an inhaled drug delivery system.616.99King's College London (University of London)http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.676976http://kclpure.kcl.ac.uk/portal/en/theses/microencapsulated-polyvinyl-alcohol-nanoparticles-for-rifampicin-delivery-to-the-lungs(45dafcac-5ec5-4ae1-8ede-bbc4e8c73c81).htmlElectronic Thesis or Dissertation
collection NDLTD
sources NDLTD
topic 616.99
spellingShingle 616.99
Sadouki, Fethi
Micro-encapsulated poly(vinyl alcohol) nanoparticles for rifampicin delivery to the lungs
description Tuberculosis is a contagious disease caused by Mycobacterium Tuberculosis and is recognised as a global public health emergency. New approaches are required to improve the chemotherapy of TB, in particular to target the reservoir of M. Tuberculosis that accumulates in alveolar macrophages and lung lesions. The aim of this thesis was to develop polymeric nanoparticle-loaded formulations for the delivery of rifampicin to the lungs. Poly (vinyl alcohol) nanospheres (NS) and nanocapsules (NC) were developed using a modified nanoprecipitation method. Both types of nanocarrier were spherical with a mean diameter of ca. 220 nm (NS) and 150 nm (NC). Rifampicin was successfully encapsulated with efficiencies of 29.3 ± 0.7% and 32.3 ± 0.3%, for NS and NCs, respectively. Methods for enhancing the stability and modifying the release of rifampicin were developed. The uptake of the PVA nanocarriers was studied in-vitro using the J774A.1 macrophage-like cell line. After 6 h incubation, the amount of rifampicin imported into macrophages by drug-loaded nanoparticles, containing 1000 μg/ml of drug, was twice (NC) or three times (NS) greater than that attained with rifampicin solution. The drug-loaded PVA nanoparticles were formulated into a powder for pulmonary administration by spray drying into lactose to yield spherical microspheres of ca. 2 μm diameter. The deposition studies of the spray dried powders, carried out using a modified twin stage impinger, showed that the NS-loaded-microspheres had a better deposition profile than the NC-loaded microspheres. This work generated novel PVA nanocarriers, demonstrated that they are effective in targeting rifampicin to macrophages and exemplified their formulation as an inhaled drug delivery system.
author2 Dailey, Lea Ann ; Jones, Stuart Allen ; Forbes, Benjamin John
author_facet Dailey, Lea Ann ; Jones, Stuart Allen ; Forbes, Benjamin John
Sadouki, Fethi
author Sadouki, Fethi
author_sort Sadouki, Fethi
title Micro-encapsulated poly(vinyl alcohol) nanoparticles for rifampicin delivery to the lungs
title_short Micro-encapsulated poly(vinyl alcohol) nanoparticles for rifampicin delivery to the lungs
title_full Micro-encapsulated poly(vinyl alcohol) nanoparticles for rifampicin delivery to the lungs
title_fullStr Micro-encapsulated poly(vinyl alcohol) nanoparticles for rifampicin delivery to the lungs
title_full_unstemmed Micro-encapsulated poly(vinyl alcohol) nanoparticles for rifampicin delivery to the lungs
title_sort micro-encapsulated poly(vinyl alcohol) nanoparticles for rifampicin delivery to the lungs
publisher King's College London (University of London)
publishDate 2014
url http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.676976
work_keys_str_mv AT sadoukifethi microencapsulatedpolyvinylalcoholnanoparticlesforrifampicindeliverytothelungs
_version_ 1718505013562572800